Sanofi scoops up U.S. biotech Inhibrx for up to $2.2 billion as it seeks to bolster pipeline; Pharma’s attack on Medicare drug price negotiation might benefit Biden

Taking stock of the drug industry, from the lab to the medicine chest

January 23, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Courtesy Sanofi STAT+ | Sanofi scoops up U.S. biotech Inhibrx for up to $2.2 billion as it seeks to bolster pipeline The deal comes as Sanofi is investing in its pipeline and seeks to convince investors its new strategy is the right course for the company. By Andrew Joseph STAT+ | Pharma's attack on Medicare drug price negotiation might benefit Biden Pharma lawsuits over Medicare drug price negotiation could benefit Biden by reminding voters he's trying to cut high prescription drug prices. By John Wilkerson The White House has a pharmacy — and it was a mess, a new investigation found The White House pharmacy was doling out drugs without much regard for pharmacy rules and regulations, according to a new investigation. By Brittany Trang

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser